This program has received financial support in the way of an educational grant from:
Kam Jorge
jkam01@amgen.com
647-241-3735
www.amgen.ca
CLINICAL EFFICACY AND SAFETY OF ACHIEVING VERY LOW LDL-CHOLESTEROL CONCENTRATIONS WITH THE PCSK9 INHIBITOR EVOLOCUMAB
CLICK TO VIEW / DOWNLOAD
EFFECT OF EVOLOCUMAB ON PROGRESSION OF CORONARY DISEASE IN STATIN-TREATED PATIENTS
CLICK TO VIEW / DOWNLOAD
EVOLOCUMAB AND CLINICAL OUTCOMES IN PATIENTS WITH CARDIOVASCULAR DISEASE
CLICK TO VIEW / DOWNLOAD
Find your Medical Sales Representative:
Medical Information Inquiries & Adverse
Event Reporting:
1-877-404-8277 (toll-free)
David Hamel
david.hamel@bayer.com
514-603-6637
www.bayer.com
Kristin Muxlow
kristin.muxlow@boehringer-ingelheim.com
705-715-3438
www.boehringer-ingelheim.ca
SELECT NON-INSULIN TREATMENTS FOR TYPE 2 DIABETES
CLICK TO VIEW / DOWNLOAD
SAD MANS BROCHURE
CLICK TO VIEW / DOWNLOAD
TYPE 2 DIABETES RISK FACTORS AND COMPLICATIONS
CLICK TO VIEW / DOWNLOAD
Don Morrison
d.morrison@hlstherapeutics.com
289-259-3609
https://www.vascepa.ca/en
Janssen Medical Information
medinfocanada@its.jnj.com
1-800-567-331
www.janssenmedicalinformation.ca
NEJM: CANAGLIFLOZIN AND RENAL OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY
CLICK TO VIEW / DOWNLOAD
2021 CCS HF GUIDELINES
CLICK TO VIEW / DOWNLOAD
ENTRESTO PROUCT MONOGRAPH
CLICK TO VIEW / DOWNLOAD
LEQVIO PRODUCT MONOGRAPH
CLICK TO VIEW / DOWNLOAD